Related Experiment Videos
[New morphine-type analgesics in anesthesia]
Cahiers D'Anesthesiologie
|April 1, 1985
Summary
New synthetic opioids, like fentanyl derivatives, offer varied potency and duration, potentially improving safety and reducing cardiovascular effects. However, their availability and clinical utility in France require further evaluation.
Area of Science:
- Pharmacology
- Anesthesiology
- Pain Management
Background:
- Fentanyl, synthesized in 1961, has led to numerous derivatives.
- Several potent analgesics are not yet available in France.
Purpose of the Study:
- To review new opioid analgesics.
- To discuss their potential clinical use and availability in France.
Main Methods:
- Literature review of opioid analgesics.
- Comparison of fentanyl derivatives (agonists) and agonist-antagonists.
Main Results:
- Fentanyl derivatives exhibit varied potency and duration of action (e.g., sufentanyl, lofentanyl, alfentanyl).
- These derivatives may offer improved safety profiles with minimal cardiovascular side effects.
- Pentazocine is the only agonist-antagonist currently available in France for pain therapy.
Conclusions:
- New opioid analgesics, particularly fentanyl derivatives, present therapeutic potential.
- Further assessment is needed for the clinical adoption of newer molecules like butorphanol, nalbuphine, and buprenorphine in France.